(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/219040 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)
A61K 31/505 (2006.01)

(21) International Application Number:
PCT/CN2021/090718

(22) International Filing Date:
28 April 2021 (28.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/018,427 30 April 2020 (30.04.2020) US

(71) Applicant: **GNT BIOTECH & MEDICALS CORPORATION** [CN/CN]; 17F., No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN).


(72) Inventors: **CHEN, Jia-Shiong**; 17F, No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN). **YANG, Mu-Hsuan**; 17F, No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN). **WU, Yi-Hong**; 17F, No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN). **CHU, Sz-Hao**; 17F, No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN). **CHOU, Cheng-Han**; 17F, No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN). **CHAO, Ye-Su**; 17F, No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN). **CHEN, Chia-Nan**; 17F, No.3, Park St., Nangang Dist., Taipei City, Taiwan 115 (CN).

(74) Agent: **LEE AND LI - LEAVEN IPR AGENCY LTD.**; Unit 2202, Tower A, Beijing Pudi Hotel, No. 7, Jian Guo Men South Avenue, Dongcheng, Beijing 100005 (CN).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,


(54) Title: HISTONE DEACETYLASE INHIBITORS FOR IMMUNOMODULATION IN TUMOR MICROENVIRONMENT




(I)



GNTbm-01



GNTbm-02



GNTbm-03

Figure 1

(57) Abstract: Provided are compounds class I HDAC inhibitors, their production and applications. The compounds possess epigenetic immunomodulatory activities in the tumor microenvironment (TME) and thus inhibit growth of tumor cells.

[Continued on next page]

WO 2021/219040 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*